Drugs / In-House Recombinant Hepatitis B (Bio Farma)
In-House Recombinant Hepatitis B (Bio Farma)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05482295 | Sep 2025 → May 2026 overdue | vaccinia | PT Bio Farma | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | In-House Recombinant Hepatitis B (Bio Farma) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05482295 ↗ |
| Modality | Vaccine | “In-House Recombinant Hepatitis B vaccine” NCT05482295 ↗ |